ArticleMolecular & cellular proteomics : MCP2019
HLA-DO Modulates the Diversity of the MHC-II Self-peptidome.
Article in Molecular & cellular proteomics : MCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- H2-O deficiency in B cells or dendritic cells drives retrovirus-neutralizing antibody responses.Journal of virology · 2026Article
- Respiratory syncytial virus inhibits type I interferon signaling to maintain HLA-DM expression in CD1ciScience · 2026Article
- T Cell Assay to Track Presentation of an Influenza Hemagglutinin Epitope Presented by the MHC-II Protein HLA-DR1.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Article
- Article
- Deficiency in non-classical major histocompatibility class II-like molecule, H2-O confers protection against Staphylococcus aureus in mice.PLoS pathogens · 2024Article
- Molecular Characteristics, Functional Definitions, and Regulatory Mechanisms for Cross-Presentation Mediated by the Major Histocompatibility Complex: A Comprehensive Review.International journal of molecular sciences · 2023Review
- The MHC Class II Antigen-Processing and Presentation Pathway Is Dysregulated in Type 1 Diabetes.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- TransMHCII: a novel MHC-II binding prediction model built using a protein language model and an image classifier.Antibody therapeutics · 2023Article
- MHC Class II Presentation in Autoimmunity.Cells · 2023Review
- H2-O deficiency promotes regulatory T cell differentiation and CD4 T cell hyperactivity.Frontiers in immunology · 2023Article
- Tuning DO:DM Ratios Modulates MHC Class II Immunopeptidomes.Molecular & cellular proteomics : MCP · 2022Article
- Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome.Frontiers in immunology · 2022Review
- Mouse Homologue of Human HLA-DO Does Not Preempt Autoimmunity but Controls Murine Gammaherpesvirus MHV68.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Yeast display of MHC-II enables rapid identification of peptide ligands from protein antigens (RIPPA).Cellular & molecular immunology · 2021Article
- MHC Class II Presentation Is Affected by Polymorphism in theJournal of immunology (Baltimore, Md. : 1950) · 2021Article
- How Does B Cell Antigen Presentation Affect Memory CD4 T Cell Differentiation and Longevity?Frontiers in immunology · 2021Review
- Distinguishing Signal From Noise in Immunopeptidome Studies of Limiting-Abundance Biological Samples: Peptides Presented by I-AFrontiers in immunology · 2021Article
- Genetic Control of Neonatal Immune Tolerance to an Exogenous Retrovirus.Journal of virology · 2020Article
- Human Hepatitis B Viral Infection Outcomes Are Linked to Naturally Occurring Variants ofJournal of immunology (Baltimore, Md. : 1950) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Presentation of antigenic peptides on MHC-II molecules is essential for tolerance to self and for initiation of immune responses against foreign antigens. DO (HLA-DO in humans, H2-O in mice) is a nonclassical MHC-II protein that has been implicated in control of autoimmunity and regulation of neutralizing antibody responses to viruses. These effects likely are related to a role of DO in selecting MHC-II epitopes, but previous studies examining the effect of DO on presentation of selected CD4 T cell epitopes have been contradictory. To understand how DO modulates MHC-II antigen presentation, we characterized the full spectrum of peptides presented by MHC-II molecules expressed by DO-sufficient and DO-deficient antigen-presenting cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.